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There  are  currently  two  major  competing  pharmaceutical 
strategies to inhibit the expression of specific genes in cells, 
animals, and also recently in humans. One is small interfer-
ing RNA (siRNA)-mediated cleavage of mRNA by the RNA 
interference mechanism, and the other is antisense oligo-
nucleotide (ASO)-triggered mRNA degradation and miRNA 
silencing.1–4 Both systems represent promising new targets 
for drug candidates for human diseases due to their broad 
applicability, high efficiency, and specificity. However, both 
targeted delivery of macromolecular drugs such as siRNA 
or ASO to the site of disease and subsequent intracellular 
targeting need to be improved before the clinical potential 
of these molecules can be realized. In the December 2011 
issue of Molecular Therapy, Moschos et al. investigate the 
potential of delivering three different Cy5-labeled oligonucle-
otides, locked nucleic acid (LNA)-modified ASO (LNA-ASO) 
with either a phosphodiester (PO-LNA), or phosphorothioate 
(PS) backbone (PS-LNA) and 2′-O-methyl modified siRNA, 
to the lungs of mice.5 Unfortunately, none of these reagents 
led to knockdown of the target mRNA or protein in any of the 
cell types investigated. However, the authors observed that 
the PS-LNA accumulated in the liver and kidney at a concen-
tration that, at least in case of the liver, was therapeutically 
relevant,  suggesting  noninvasive  pulmonary  delivery  as  a 
possible route for administration of oligonucleotide therapeu-
tics to the liver and kidney.
Human diseases are often associated with deregulation 
of  gene  expression,  either  as  a  primary  cause  or  as  an 
outcome of other events. Disease symptoms can, in many 
instances, be alleviated by inhibiting gene expression through 
the  delivery  of  oligonucleotides. Various  methods,  includ-
ing  include  nanocarrier  delivery,6  chemical  modification,7 
and   conjugation8 have been used to facilitate the delivery 
of   oligonucleotides. Traditionally, systemic delivery of oligo-
nucleotide drugs has been performed by intravenous injec-
tion of either naked molecules or within delivery systems, but 
nonspecific accumulation in various tissues has favored local 
delivery routes such as to the lungs so as to ensure direct 
access to the target site.
Delivery to the lung will be key to moving RNA interference 
and antisense technology into the clinic. The lungs represent 
the site of entry and intracellular establishment of many air-
borne  pathogens  including  viruses  (e.g.,  influenza,  SARS, 
RSV, and common cold) and bacteria (e.g., Streptococcus 
pneumonia,  Mycoplasma  pneumonia,  Neisseria  meningiti-
des, and Mycobacterium tuberculosis) and is a frequent site 
of tumor development, genetic diseases (e.g., cystic fibrosis), 
and immunological disorders (e.g.,   bronchitis, asthma, lung 
fibrosis,  and  chronic  obstructive  pulmonary  disease).  How-
ever, the translocation of oligonucleotide-based drugs across 
the  pulmonary  mucosal  epithelia  is  hampered  by  several 
biological barriers. These include the physical barriers of the 
overlying mucus layer and the tight packing of epithelial cells 
combined with the sweeping movement of apical cilia that 
removes luminal material away from the mucosal surface.9 In 
addition, both naked and formulated siRNA and ASO are vul-
nerable to recognition and subsequent destruction by alveo-
lar macrophages that are part of the mononuclear phagocyte 
system. After reaching the target cells, the oligonucleotides 
must transfer across the cell membrane, escape hydrolytic 
destruction in the endosomes, and interact with the mRNA 
target before translation.
In the new study, Moschos et al. administered naked oligo-
nucleotides by the intratracheal route to luciferase-expressing 
mice and studied cell-type uptake and activity of the oligonucle-
otides using a tissue disruption and cell sorting method involv-
ing fractionation of pulmonary cell types.5 Disappointingly, the 
initial result showed no knockdown effect in any of the lung cell 
types with any of the tested oligonucleotides. However, inves-
tigation of the biodistribution of the dye-  labeled material and 
mass spectrometric analysis provided a more detailed picture 
of oligonucleotides deposition in lung tissue and subsequent 
systemic transfer into other tissues. The PO-LNA and siRNA 
levels decreased over 24 hours (with the siRNA virtually absent 
after 1 hour) with rapid renal clearance evident after only 15 
minutes. In contrast, the   thiol-containing PS-LNA was retained 
as discreet, particulate structures within macrophages and to a 
lesser extent in alveolar and bronchial epithelia. After 24 hours, 
accumulation of PS-LNA was also observed in submucosal 
membranes and endothelial cells, but surprisingly no knock-
down of the target mRNA or protein could be detected in any 
of the cell types. Despite this negative finding, the study yielded 
another surprising and potentially useful result for the PS-LNA 
construct. The PS-LNA accumulated in the liver and kidney at 
concentrations that, at least in case of the liver, was therapeuti-
cally relevant, demonstrated by an efficient knockdown of the 
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liver specific apolipoprotein BmRNA. Notably, the potency was 
comparable to the result obtained when the same amount of 
PS-LNA was injected via the intravenous route. This is a highly 
interesting observation that promotes noninvasive pulmonary 
delivery as a realistic route for administration of oligonucleotide 
therapeutics to the liver and kidney.
The lack of functional activity of naked ASO and siRNA 
in  the  lung  contradicts  many  other  reports  conducted  in 
  animals10–12 and humans.13 The discrepancies may be due 
to differences in the experimental set up, but another expla-
nation, to which Moschos et al.5 allude, is the problem of 
nonspecific cellular effects induced mainly by Toll-like recep-
tor type 3 and 7 signaling by double- and single-stranded 
oligonucleotides,  respectively.14–16  Different  oligonucleotide 
sequences, structures, and patterns of chemical modifica-
tions in the various constructs applied could account for the 
different results observed between the different studies.
The results presented in this article and others17 also high-
light the importance of combining LNA-ASO or siRNA with 
delivery reagents to increase the efficiency of gene knockdown 
in pulmonary tissue. Successful knockdown experiments in 
lung tissue has been reported using lipids18 and polyplexes,19 
which  may  be  attributed  to  higher  stability,  increased  resi-
dence time in the lung, improved cell membrane penetration, 
and  escape  from  the  endosomal  compartment. There  is  a 
necessity, however, to use materials that limit adverse immu-
nological response and possible cellular damage. Optimiza-
tion of the delivery system and oligonucleotide design are 
important considerations that need to be addressed in order 
to enable the clinical application of pulmonary nucleic acid–
based therapeutics.
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Figure 1  Intratracheal delivery and macrophage capture of PS-LNA in the mouse lung based on the results obtained by Moschos et al.5 PS-LNA accumulates   
within macrophages and alveolar cells which further facilitated systemic migration to the kidney and liver. LNA, locked nucleic acid; PS, phosphorothioate.
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